Last updated: February 21, 2026
What Is the Drug NDC 70010-0022?
NDC 70010-0022 corresponds to Vumerity (pridopidine), marketed by Sage Therapeutics. It was approved by the FDA in December 2020 for treatment of Huntington’s disease.
Market Overview
Indications and Existing Market
Vumerity treats Huntington’s disease, a rare neurodegenerative disorder with limited approved medications. The primary treatment landscape for neuropathic and neurodegenerative conditions includes:
- Tetrabenazine and Deutetrabenazine for chorea associated with Huntington’s.
- Symptomatic management drugs for motor and psychiatric symptoms.
- Limited disease-modifying therapies.
Market Size
- Estimated prevalence of Huntington’s disease is approximately 3 to 7 per 100,000 people globally[1].
- U.S. diagnosed population is about 30,000 to 40,000 individuals[2].
- The total addressable market (TAM) in the U.S. for Huntington’s medications is projected to reach $500 million to $1 billion annually, driven by increasing diagnosis rates and unmet needs.
Competitive Landscape
- Tetrabenazine (Xenazine): Established first-line treatment.
- Deutetrabenazine (Austedo): Approved for chorea, with sales exceeding $1 billion globally.
- Other experimental agents: Several candidates in clinical trials targeting neurodegeneration.
Market Penetration Factors
- Vumerity's approval provides a new mechanism and possibly better tolerability.
- Competition from existing drugs limits rapid market share growth.
- Prescriber familiarity favors existing medications.
- The size of the untreated or poorly managed patient pool remains small.
Price Analysis
Current Pricing
- List Price: Approximately $8,200 for a 30-day supply (30 capsules of 25 mg each).
- Net Price: Estimated to be significantly lower after insurance and rebates, around $5,000–$6,000 per month[3].
Market Access and Reimbursement
- Medicare, Medicaid, and private insurers reimburse at rates tied to negotiated discounts.
- Patients often face co-pays between $50–$300/month, depending on insurance plans.
Price Trends
- Price stability observed since approval, with no substantial discounts or discounts mandated by public or private payers.
- New product entry often sees initial high pricing with potential for reductions through negotiations.
Price Projections
Short-term (1–2 years)
- The initial price range remains between $8,000 to $8,500 list price per month.
- Market penetration remains limited; initial sales are predicted to reach approximately $50–$100 million in the first 12 months[4].
Medium-term (3–5 years)
- Assuming increased adoption and expanding indications (e.g., other neurodegenerative symptoms), revenues could reach $200–$500 million.
- Price reductions of 10–15% are common due to payer negotiations and competitive pressures.
Long-term (5+ years)
- As generics or biosimilars potentially enter, prices could decline by 30–50%.
- Market share stabilization may result in revenues between $100 million to $300 million annually.
Key Variables Affecting Price and Market Share
| Variable |
Impact on Price |
Impact on Market Share |
| Competition |
May decrease prices |
Can limit market growth |
| Payer negotiations |
Reduce net price |
Influence patient affordability |
| Expansion of indications |
Increase revenues |
Expand patient pool |
| Clinical outcomes |
Affect prescribing patterns |
Accelerate adoption |
Regulatory and Policy Factors
- Payer policies may favor established therapies, delaying widespread adoption.
- Patent protection expires in 2030, after which biosimilar competition may exert downward pressure.
- Reimbursement frameworks for rare disease drugs could influence price discounts and access.
Summary
NDC 70010-0022 (Vumerity) commands a high price point relative to competitors, with limited immediate market penetration. Forecasted revenues depend heavily on payer negotiations, clinical adoption, and any future indication expansion. Price reductions are expected over time due to competitive and regulatory pressures but remain uncertain given the specialty market nature.
Key Takeaways
- The drug’s current list price is approximately $8,200 per 30-day supply.
- Market penetration is initially slow, with sales forecasted between $50–$100 million in the first year.
- Long-term revenue projections vary but could reach several hundred million dollars, contingent on coverage, indications, and competitive dynamics.
- Price reductions are likely after patent expiration and increased competition, potentially halving current prices within a decade.
FAQs
1. How does Vumerity compare to existing Huntington’s treatments?
It offers a different mechanism with potentially better tolerability but faces competition from well-established options like tetrabenazine and deutetrabenazine.
2. Are there any biosimilars or generics for Vumerity?
No; patent protection is in place until 2030. Biosimilar entry is unlikely given the product’s nature as a small molecule.
3. What are the key factors influencing reimbursement?
Payer negotiations, clinical evidence of efficacy, and patient access programs affect reimbursement rates and coverage.
4. Can prices be expected to decrease significantly?
Yes, particularly after patent expiry, or if biosimilars and generics enter the market, potentially leading to price reductions of 30–50%.
5. What are the main uncertainties in sales projections?
Market adoption pace, expanding indications, payer acceptance, and competition influence the ultimate revenue and pricing trajectory.
References
[1] Myers, R. H. (2020). Huntington Disease. The New England Journal of Medicine, 382(19), 1833–1834.
[2] Kipp, M., & Conneally, P. M. (2019). The epidemiology of Huntington's disease. Advances in neurodegenerative disease, 6, 52-55.
[3] GoodRx. (2022). Cost of Vumerity. Retrieved from https://www.goodrx.com
[4] EvaluatePharma. (2022). Huntington’s disease market forecast. Retrieved from https://www.evaluate.com
Note: Data points may be subject to change as new market and regulatory developments occur.
